FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1981-1983 November 6, 2008 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

September 2008 marked the beginning of a new federal program intended to promote the development of pharmaceutical products for so-called neglected diseases — infectious diseases that disproportionately affect poor populations in developing countries. Implemented by the Food and Drug Administration (FDA) Amendments Act of 2007, this program will give the sponsor of a drug for a tropical disease a "voucher" entitling the company to expedited FDA review of a new drug application for any other product it makes.¹

The need to encourage additional research in this field is clear. Diseases such as tuberculosis, malaria, leishmaniasis, and trypanosomiasis affect millions of . . . [Full Text of this Article]

Source Information

Dr. Kesselheim is a patent attorney and an instructor in medicine in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital, Harvard Medical School, Boston.

Related Letters:

FDA Review Vouchers
Moe J., Grabowski H., Ridley D., Kesselheim A. S.
Extract | Full Text | PDF  
N Engl J Med 2009; 360:837-838, Feb 19, 2009. Correspondence

This article has been cited by other articles:

• Anderson, G. F. (2009). Spurring New Research For Neglected Diseases. Health Aff (Millwood) 28: 1750-1759 [Abstract] [Full Text]  
• Moe, J., Grabowski, H., Ridley, D., Kesselheim, A. S. (2009). FDA Review Vouchers. NEJM 360: 837-838 [Full Text]